Paroxysmal atrial fibrillation: treatment choice

Paroxysmal atrial fibrillation: treatment choice

Characteristics and classification of various paroxysmal atrial fibrillation (AF) forms are presented. Main indications for sinus rhythm restoration are listed, together with characteristics of principal medications used for AF management. Antiarrhythmic choice issue is discussed, with emphasis on i...

Full description

Bibliographic Details
Main Author:	B. A. Tatarsky
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2007-06-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	atrial fibrillation pharmaceutical cardioversion antiarrhythmic therapy effectiveness and safety
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1257

Similar Items

PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015-12-01)

Pharmacological cardioversion of atrial fibrillation paroxysm in elderly and senile patients at prehospital stage
by: Andrei V. Syrov
Published: (2021-03-01)

Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation
by: I. G. Fomina, et al.
Published: (2005-08-01)

Incidence and Determinants of Spontaneous Cardioversion of Early Onset Symptomatic Atrial Fibrillation
by: Marco Valerio Mariani, et al.
Published: (2022-10-01)

Strategy and tactics of emergency treatment of atrial fibrillation: a modern approach to the problem
by: Yu. A Bunin
Published: (2015-03-01)

Intravenous Cavutilide for Pharmacological Conversion of Paroxysmal and Persistent Atrial Fibrillation in Patients with Heart Failure
by: Maria M. Beliaeva, et al.
Published: (2023-12-01)

Efficacy and Safety of Bepridil for Patients with Persistent Atrial Fibrillation after Failed Electrical Cardioversion
by: Yasuyuki Egami, MD, et al.
Published: (2011-01-01)

Guidelines for the clinical management of atrial fibrillation: a practical perspective
by: E Blanc, et al.
Published: (2004-05-01)

Efficiency and safety of pharmacological cardioversion for atrial fibrillation
by: Aleksei V. Tarasov
Published: (2021-04-01)

Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study
by: Yu. A. Bunin, et al.
Published: (2005-12-01)

Propafenone efficacy in paroxysmal atrial fibrillation
by: V. V. Skibitsky, et al.
Published: (2004-12-01)

Analysis of drug-induced and spontaneous cardioversions reveals similar patterns leading to termination of atrial fibrillation
by: Arne van Hunnik, et al.
Published: (2024-07-01)

CARDIOVERSION WITH BI- AND MONOPHASE DEFIBRILLATORS IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION
by: V. A. Lusov, et al.
Published: (2010-02-01)

The efficacy of synchronized direct current shock in reverting long standing persistent atrial fibrillation in to sinus rhythm. What help to achieve high success rate?
by: AMAR Talib AL-HAMDI, et al.
Published: (2021-05-01)

PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE TREATMENT OF PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION IN EVERY DAY CLINICAL PRACTICE
by: I. V. Graifer, et al.
Published: (2016-01-01)

THE IMPORTANCE OF EARLY CARDIOVERSION OF PAROXYSMAL ATRIAL FIBRILLATION
by: Franc Verovnik
Published: (2002-01-01)

Radiofrequency ablation and antiarrhythmic therapy in the treatment of patients with paroxysmal and persistent atrial fibrillation: clinical effects
by: M. G Bubnova, et al.
Published: (2015-09-01)

Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter
by: D. A. Gagloeva, et al.
Published: (2023-05-01)

Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety
by: N. Yu. Mironov, et al.
Published: (2021-11-01)

Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter
by: E B Maĭkov, et al.
Published: (2015-01-01)

Antiarrhythmic therapy in the treatment of atrial fibrillation: yesterday, today, tomorrow
by: V. I. Podzolkov, et al.
Published: (2019-06-01)

Insights from clinical trials: New evidence supports surgical interventions over drug therapies for atrial fibrillation
by: Akshat D. Modi, et al.
Published: (2024-06-01)

Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness
by: N. Yu. Mironov, et al.
Published: (2021-05-01)

Paroxysms of atrial fibrillation and stages of the reproductive system aging in women
by: R.F. Rakhmatullov, et al.
Published: (2022-06-01)

Frequency Analysis of Atrial Fibrillation From the Surface Electrocardiogram
by: Daniela Husser, et al.
Published: (2004-07-01)

ANALYSIS OF THE RESULTS OF FIVE YEAR PATIENTS FOLLOW-UP IN PAROXYSMAL ATRIAL FIBRILLATION TREATED WITH ANTIARRHYTHMICS
by: T. A. Rybakova, et al.
Published: (2018-08-01)

ATRIAL FIBRILLATION: CURRENT PROBLEMS AND PROSPECTS OF MEDICAL CARE, TREATMENT AND PREVENTION
by: Ju. P. Skirdenko, et al.
Published: (2016-05-01)

Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety
by: N. Yu. Mironov, et al.
Published: (2019-01-01)

PROSPECTS FOR THE TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION
by: V. A. Sulimov, et al.
Published: (2016-01-01)

Personalized Medicine in the Treatment of Atrial Fibrillation: Myth or Reality?
by: V. I. Podzolkov, et al.
Published: (2019-03-01)

Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness
by: N. Yu. Mironov, et al.
Published: (2018-11-01)

Current strategies of antiarrhythmic drug therapy for paroxysmal atrial fibrillation
by: Takashi Komatsu
Published: (2012-06-01)

A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation
by: Morten Lock Hansen, et al.
Published: (2024-07-01)

Current Status of Internal Cardioversion in Atrial Fibrillation.
by: Andreas Plewan, et al.
Published: (2002-04-01)

EFFECT OF SPIRAPRIL ON THE LENGTH OF INTERICTAL INTERVAL IN PAROXYSMAL ATRIAL FIBRILLATION
by: L. N. Chikhireva, et al.
Published: (2015-12-01)

Tactics of Antiarrhythmic Therapy in Comorbid Elderly and Senile Patients with Paroxysmal and Recurrent Atrial Fibrillation
by: M. H. Fedorova, et al.
Published: (2018-11-01)

Acute Management of Paroxysmal Atrial Fibrillation with Intravenous Flecainide plus Oral Beta-Blockers
by: Athanasios Kartalis, et al.
Published: (2024-06-01)

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion
by: Ozan Demirel, et al.
Published: (2023-05-01)

The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model
by: Felix Wiedmann, et al.
Published: (2021-01-01)

Pharmacological Treatment for Atrial Fibrillation
by: Kaoru Sugi, MD PhD, et al.
Published: (2005-01-01)